Valuation: Cardiol Therapeutics Inc.

Market Cap 174M 123M 108M 99.15M 92.82M 11.57B 178M 1.19B 461M 5.72B 461M 451M 19.83B P/E 2026 *
-4.19x
P/E 2027 * -6.49x
Enterprise Value 159M 112M 98.29M 90.6M 84.82M 10.57B 162M 1.09B 421M 5.23B 421M 412M 18.12B EV / Sales 2026 *
-
EV / Sales 2027 * 49.3x
Free-Float
97.62%
Yield 2026 *
-
Yield 2027 * -
05-12 Cardiol Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-07 Cardiol Adds Results "Further Validate" Ongoing Phase III Trial, Which Recently Surpassed 75% Enrollment MT
05-07 Cardiol Says Results Demonstrate CardiolRx "May Represent a Paradigm Shift" In the Treatment of Patients With Recurrent Pericarditis MT
05-07 Cardiol Therapeutics Says Its Phase II MAvERIC Results Accepted For Publication In The Journal Of The American Heart Association MT
05-07 Cardiol Therapeutics Inc Announces Phase II Maveric Results Accepted for Publication in the Journal of the American Heart Association CI
04-28 Cardiol Therapeutics Up In US Premarket As Expands Phase 3 Maveric Trial to Include 7 More Clinical Centers in the U.S. MT
04-28 Cardiol Therapeutics Inc. Expands Maveric Phase III Trial Network and Provides Clinical Updates on Cardiolrx CI
04-01 Cardiol Therapeutics Fiscal 2025 Loss Narrows; Says Now Fully Funded Through Completion of MAVERIC trial MT
04-01 Cardiol Therapeutics initiated pivotal Phase III Maveric trial of Cardiolrx in recurrent pericarditis RE
04-01 Cardiol Therapeutics Inc. Provides Update on Strategic Priorities CI
03-31 Cardiol Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
02-10 Cardiol Therapeutics Inc. Announces the Publication of Results from Its Phase II Archer Study in ESC Heart Failure CI
01-23 Cardiol Therapeutics Inc. announced that it has received CAD 13.500001 million in funding CI
1 week+0.33%
Current month-10.65%
1 month-15.64%
3 months-12.21%
6 months+9.42%
Current year+15.27%
1 week 1.47
Extreme 1.47
1.56
1 month 1.43
Extreme 1.43
1.74
Current year 1.22
Extreme 1.225
2.33
1 year 1.22
Extreme 1.225
2.33
3 years 0.91
Extreme 0.91
4.26
5 years 0.61
Extreme 0.61
6.19
10 years 0.61
Extreme 0.61
8.49
Manager TitleAgeSince
Chief Executive Officer - 19/01/2017
Director of Finance/CFO - 16/08/2018
Chief Operating Officer - 03/12/2020
Director TitleAgeSince
Director/Board Member - 15/12/2017
Director/Board Member - 19/01/2017
Chairman - 07/07/2021
Date Insider Type Main position Quantity % Market Cap.
01-03Option

Director

15,594 0.0156%
01-03Option

Chief Financial Officer

39,692 0.0397%
01-03Option

Director

15,594 0.0156%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.33%-21.56%+42.45% 123M
-0.48%+7.20%-5.65%+1.02% 46.2B
+2.19%+11.71%+393.31%+580.42% 38.71B
+2.53%+13.93%+21.38%-12.81% 31.9B
+1.65%+3.61%+16.04%+55.62% 31.12B
-4.16%-2.58%+8.94%+25.31% 23.77B
-0.32%+12.96% - - 16.2B
+1.37%+14.53%+69.64%+130.07% 15.05B
+1.00%+10.30%+13.31%+20.31% 13.74B
+3.63%+9.53%+103.97%+98.73% 13.42B
Average +0.74%+8.26%+66.60%+104.57% 23.02B
Weighted average by Cap. +0.75%+8.70%+88.68%+130.84%

Financials

2026 *2027 *
Net sales - 3.32M 2.34M 2.05M 1.89M 1.77M 221M 3.39M 22.74M 8.8M 109M 8.79M 8.6M 378M
Net income -35.21M -24.82M -21.76M -20.06M -18.78M -2.34B -35.94M -241M -93.27M -1.16B -93.18M -91.15M -4.01B -30.57M -21.55M -18.89M -17.41M -16.3M -2.03B -31.21M -209M -80.99M -1B -80.91M -79.14M -3.48B
Net Debt -15.01M -10.58M -9.27M -8.55M -8M -998M -15.32M -103M -39.76M -493M -39.72M -38.85M -1.71B -10.26M -7.23M -6.34M -5.84M -5.47M -682M -10.47M -70.21M -27.17M -337M -27.14M -26.55M -1.17B
Logo Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
Employees
18
Date Price Change Volume
26/06/26 CA$1.510 0.00% 22,177
25/06/26 CA$1.510 +1.34% 48,612
24/06/26 CA$1.490 -0.67% 25,574
23/06/26 CA$1.500 -0.99% 30,833
22/06/26 CA$1.515 +0.66% 12,801
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.510CAD
Average target price
6.000CAD
Spread / Average Target
+297.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRDL Stock